Bronchiolitis: doing less and still getting better.

Infection with respiratory syncytial virus (RSV) is among the universal experiences of childhood. Worldwide, by 1 year of life, half of all children have been infected with RSV and by 2 years of age, virtually all children have been infected with RSV. Unlike many viral infections, it is the prevalence, as opposed to the severity, of infection that motivates our collective focus on the optimal treatment course for infants with RSV. Although acknowledging that in some small subset of high-risk infants, preventive strategies are justified, the focus of this commentary concerns a randomized, controlled trial of treatment with nebulized hypertonic saline in infants with acute bronchiolitis published in this issue of Pediatrics.